Post-Infection Inflammation Resolution Support Protocol

SPMs are biosynthesized from polyunsaturated fatty acid precursors: E-series resolvins derive from EPA, while D-series resolvins, protectins, and maresins derive from DHA [id=20]. Increasing dietary intake of EPA and DHA-rich foods (cold-water fatty fish, algae-based sources) elevates RBC membrane phospholipid EPA+DHA content, the substrate pool available for enzymatic conversion to SPMs during the resolution phase [id=23].

Arachidonic acid (AA), an omega-6 PUFA, competes with EPA and DHA for the same lipoxygenase (LOX) enzymatic pathways involved in SPM synthesis [id=20]. While AA also serves as a substrate for lipoxins — the first-described SPMs — an excessively high omega-6:omega-3 ratio may bias the system toward pro-inflammatory eicosanoid output over pro-resolving mediator output [id=19]. The literature suggests moderating sources of excess linoleic acid (refined seed oils, ultra-processed foods) during the resolution window.

The resolution phase of inflammation is an active, resource-dependent biological programme requiring intact neuroimmune signalling [id=19]. SPM synthesis and macrophage-mediated efferocytosis are metabolically demanding processes; sleep disruption is known to perturb immune regulation. The paradigm of resolution as active — not passive — implies that recovery states such as sleep are not merely symptomatic relief but may be mechanistically permissive for resolution mediator biosynthesis and action [id=20].

Chronic stress promotes sustained pro-inflammatory eicosanoid signalling and may blunt the transition from the initiation phase to active resolution [id=19]. The pro-resolving mediator network — lipoxins, resolvins, protectins, maresins — represents the biological counterweight to pro-inflammatory prostaglandins and leukotrienes; conditions that chronically upregulate the latter may competitively suppress SPM-mediated resolution [id=20]. The literature conceptually supports stress reduction as a means of not driving repeated pro-inflammatory cycles that exhaust resolution capacity.

EPA and DHA are the direct precursors to the E-series and D-series resolvins, protectins, and maresins — the principal SPM families that actively terminate neutrophil recruitment, stimulate efferocytosis, and restore tissue homeostasis following infection [id=20]. Supplemental fish oil or algae-derived DHA/EPA raises the omega-3 index in a dose-dependent manner, expanding the RBC membrane substrate reservoir available for SPM production [id=23].

Lipoxins (LXA4, LXB4), derived from arachidonic acid via sequential LOX action, were the first SPMs characterized and function to halt neutrophil chemotaxis and initiate monocyte recruitment for apoptotic cell clearance [id=20]. The resolution cascade described by Serhan and colleagues positions lipoxins as key early 'stop signals' in the initiation-to-resolution transition [id=19]. Nutritional strategies that preserve adequate AA availability while avoiding excess may support this arm of the SPM network.

Moderate physical activity is associated with macrophage phenotype modulation and supports the efferocytosis and tissue-clearance functions central to resolution [id=77]. Vigorous exercise immediately post-infection may re-amplify pro-inflammatory signalling; the resolution literature supports a graduated return to activity that does not overwhelm the SPM-mediated clearance capacity [id=19].

Strenuous exercise generates its own pro-inflammatory eicosanoid cascade that competes with the resolution programme [id=19]. In the context of post-infection inflammation, excessive training load before resolution is complete may impair the shift from neutrophil-dominant inflammation to macrophage-mediated clearance and tissue repair, a transition critically dependent on SPM signalling [id=20].

The omega-3 index — EPA + DHA as a percentage of total RBC membrane phospholipid fatty acids — is the standardized, clinically validated biomarker for tissue omega-3 status and a proxy for SPM production capacity [id=23]. Obtaining a baseline measurement allows personalization of dietary and supplement strategies, and a follow-up measurement at 8–12 weeks reflects the ~120-day RBC lifespan-dependent incorporation rate.

Resolution, as an active process, follows a temporal programme: neutrophil influx peaks, then resolution mediators shift macrophage phenotype toward efferocytosis and debris clearance [id=19]. Monitoring symptom duration, swelling, pain, and fatigue trajectory provides a clinical correlate of resolution kinetics. Prolonged or re-emerging inflammatory signs may indicate impaired resolution capacity rather than persistent infection, a distinction with direct therapeutic implications [id=77].

Efferocytosis — the phagocytic clearance of apoptotic neutrophils and debris by macrophages — is a central mechanistic step in tissue resolution and restoration of homeostasis [id=77]. Gene-expression and immune infiltration analyses identify efferocytosis-related gene signatures as relevant to inflammatory burden and resolution capacity [id=77]. Where advanced diagnostics are accessible, immune cell profiling or soluble efferocytosis markers may help stratify patients with impaired resolution.

EPA and DHA at doses above 3 g/day have antiplatelet properties reported in the literature, potentially augmenting bleeding risk in patients on anticoagulants or antiplatelet agents [id=23]. The omega-3 index elevation strategy relies on supplemental EPA+DHA, and clinicians should weigh SPM substrate benefits against bleeding risk in this population [id=20].

The resolution biology described here — SPM synthesis, efferocytosis, lipoxin-mediated stop signals — operates in the post-infectious phase, after pathogen burden is controlled [id=19]. This protocol addresses resolution support, not pathogen clearance. Using pro-resolving nutritional strategies during active uncontrolled infection without appropriate antimicrobial therapy is not supported by the resolution literature and could delay effective treatment [id=19, id=20].

Efferocytosis is a macrophage-dependent clearance process; patients with primary immunodeficiencies, post-transplant immunosuppression, or conditions involving macrophage dysfunction may have structurally impaired resolution capacity that cannot be fully addressed through substrate or lifestyle interventions alone [id=77]. Transcriptomic analyses highlight that efferocytosis-gene dysregulation is a disease-level phenomenon in some inflammatory conditions, not simply a substrate-availability problem [id=77].